hit counter
ChemoCentryx, Inc. (CCXI) Stock News Sentiment & Price - Sentifly
CCXI - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



ChemoCentryx, Inc. (CCXI)

USA
Biotechnology
NASDAQ
CCXI Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CCXI Latest news
Zacks Investment Research
Positive
ChemoCentryx (CCXI) Q3 Loss Narrower Than Expected, Sales Top
2021-11-10 12:14

ChemoCentryx (CCXI) posts narrower-than-expected loss for third-quarter 2021. The company's revenues for the quarter also beat estimates.

GlobeNewsWire
Neutral
ChemoCentryx to Participate in Two Upcoming Investor Conferences
2021-11-10 08:00

SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences:

The Motley Fool
Neutral
Big Pharma Is Going Holiday Shopping. Who's Next?
2021-11-10 06:20

After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.

Seeking Alpha
Neutral
ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2021 Results - Earnings Call Transcript
2021-11-09 23:51

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research
Positive
ChemoCentryx (CCXI) Reports Q3 Loss, Tops Revenue Estimates
2021-11-09 19:49

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 30.44% and 20.70%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research
Positive
Should You Buy ChemoCentryx (CCXI) Ahead of Earnings?
2021-11-08 10:45

ChemoCentryx (CCXI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

GlobeNewsWire
Neutral
Abstracts at the Annual Meetings of the American Society of Nephrology and American College of Rheumatology Highlight Potential Value of TAVNEOS™ (avacopan)
2021-11-04 08:30

SAN CARLOS, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the abstracts accepted for presentation and publication as part of the annual meetings of the American Society of Nephrology (ASN) Kidney Week 2021 and American College of Rheumatology (ACR) Convergence 2021, taking place November 2-7, 2021 and November 3-9, 2021, respectively.

GlobeNewsWire
Neutral
ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021
2021-11-02 08:30

MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close on Tuesday, November 9, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on November 9, 2021 to discuss these results and to answer questions.

Zacks Investment Research
Positive
ChemoCentryx (CCXI) Expected to Beat Earnings Estimates: Should You Buy?
2021-11-01 16:06

ChemoCentryx (CCXI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Forbes
Positive
What's Next For ChemoCentryx Stock After Over A 100% Rise In A Month?
2021-10-21 10:00

The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat autoimmune diseases and inflammatory disorders, has skyrocketed with a 104% rise over the last month. This can be attributed to an unexpected U.S. FDA approval of Tavneos - an oral drug

Loading more news...